Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Co., Ltd., has received a drug clinical trial approval notice from the National Medical Products Administration for Hybomet-Atorvastatin Calcium Tablets (10mg/20mg). The tablets are intended to treat adult patients with primary hypercholesterolemia or mixed dyslipidemia whose LDL-C levels remain inadequately controlled with statin monotherapy, in conjunction with dietary management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments